Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISRADIPINE vs ADALAT CC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.
Hypertension,Chronic stable angina
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
Terminal elimination half-life: 7-10 hours; clinical context: sustained-release formulation provides therapeutic concentrations over 24 hours with once-daily dosing, but half-life does not directly reflect drug effect duration due to slow absorption.
Hepatic metabolism via CYP3A4 isoenzyme; undergoes extensive first-pass metabolism.
Hepatic metabolism via CYP3A4; nifedipine is converted to inactive metabolites.
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Renal: 70-80% as metabolites, fecal: 15-20% as metabolites, biliary: minimal (<5% unchanged).
96%, primarily to alpha-1-acid glycoprotein and albumin.
92-98% bound primarily to albumin.
2.9 L/kg (3-5 L/kg reported); clinical meaning: extensive tissue distribution, high affinity for vascular smooth muscle.
1.2-1.6 L/kg; clinical meaning: indicates extensive tissue distribution, with higher concentrations in organs such as liver and kidney, and lower in brain due to P-glycoprotein efflux.
Oral: 15-24% (first-pass effect); sustained-release: approximately 30% due to reduced presystemic metabolism.
65-90% after oral administration; absolute bioavailability of nifedipine in ADALAT CC: approximately 65% due to first-pass metabolism in liver and gut wall.
No dose adjustment required for mild to moderate renal impairment (GFR >30 m L/min). For severe renal impairment (GFR <30 m L/min), initiate at 2.5 mg twice daily and titrate cautiously.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), start at 30 mg once daily and titrate cautiously.
For Child-Pugh Class A or B: initiate at 2.5 mg twice daily and titrate cautiously. For Child-Pugh Class C: use isradipine with caution; consider starting at 2.5 mg once daily and adjust based on response and tolerability.
For mild to moderate hepatic impairment (Child-Pugh A or B), reduce initial dose to 30 mg once daily; for severe impairment (Child-Pugh C), contraindicated or use with extreme caution.
Not FDA-approved for pediatric use. Limited data: initial dose 0.05-0.15 mg/kg orally 3-4 times daily; maximum 0.8 mg/kg/day.
Safety and efficacy not established; use is not recommended in pediatric patients.
Initiate at 2.5 mg twice daily; titrate slowly due to increased risk of hypotension. Maximum dose usually 5 mg twice daily.
Initiate at 30 mg once daily; titrate slowly due to increased risk of hypotension and higher drug exposure. Monitor closely.
None
No FDA black box warning.
May cause hypotension, peripheral edema, heart failure exacerbation (particularly in patients with pre-existing left ventricular dysfunction), and increased angina or myocardial infarction upon abrupt withdrawal. Use caution in patients with aortic stenosis, hepatic impairment, and in elderly patients. May cause gingival hyperplasia. Should be used with caution in patients with severe left ventricular dysfunction or heart failure.
Beta-blocker withdrawal: taper if discontinuing; exacerbation of angina,Heart failure: use caution in patients with severe left ventricular dysfunction,Hepatic impairment: reduce dose,Peripheral edema: may occur; differentiate from worsening heart failure,Monitor blood pressure during initiation and titration
Hypersensitivity to isradipine or any dihydropyridine calcium channel blocker; cardiogenic shock; unstable angina; acute myocardial infarction (within first 4 weeks); severe aortic stenosis; second- or third-degree AV block (unless pacemaker present); sick sinus syndrome (unless pacemaker present); concomitant administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir) due to increased risk of toxicity.
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concurrent use with strong CYP3A4 inducers (e.g., rifampin)
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and can increase isradipine levels, leading to toxicity. High-fat meals may slow absorption but do not significantly alter overall effect. No other specific dietary restrictions.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, raising nifedipine levels and risk of toxicity. High-fat meals may increase absorption; take consistently with respect to meals. Avoid alcohol as it may exacerbate hypotension.
Isradipine is a pregnancy category C drug. In animal studies, it caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies) at doses 2-3 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk. First trimester: potential for teratogenic effects. Second and third trimesters: may cause fetal hypoxia, IUGR, and preterm delivery due to maternal hypotension; also associated with decreased uterine blood flow.
Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotoxicity, fetotoxicity, and teratogenicity (e.g., digital anomalies, cleft palate) at doses several times the maximum recommended human dose. In humans, data are limited but there is no clear evidence of a significant increase in major congenital malformations. First trimester exposure is not strongly associated with major defects; however, some studies suggest a possible small increase in oral clefts. Second and third trimester use may cause maternal hypotension and subsequent fetal distress (e.g., reduced uteroplacental perfusion). Use near term may theoretically inhibit labor, but nifedipine is used as a tocolytic for preterm labor. Overall, the risk is considered low; however, fetal monitoring is recommended if used in pregnancy. FDA Pregnancy Category C (prior to 2015 categorization).
Isradipine is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.14. Low concentrations are expected; based on limited data, the relative infant dose is <1% of maternal weight-adjusted dose. However, due to potential for adverse effects in nursing infants (e.g., hypotension), caution is advised. Consider benefits of breastfeeding and importance of drug to mother.
Nifedipine is excreted into human breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.56 to 1.0 based on limited data. The estimated daily infant dose via milk is less than 5% of the maternal weight-adjusted dose, which is considered clinically insignificant. No adverse effects have been reported in breastfed infants. However, caution is advised, especially with high maternal doses or prolonged use. The American Academy of Pediatrics considers nifedipine compatible with breastfeeding.
Pregnancy may alter the pharmacokinetics of isradipine due to increased plasma volume, renal clearance, and hepatic metabolism. No specific dose adjustment guidelines are established; however, higher doses may be required to achieve therapeutic effect. Conversely, increased sensitivity to hypotensive effects may necessitate dose reduction. Individualize dosing based on blood pressure response and tolerance. Start at low doses and titrate carefully.
Pregnancy may alter the pharmacokinetics of nifedipine due to increased plasma volume and altered hepatic metabolism. However, specific dosing adjustments for Adalat CC in pregnancy are not well established. In clinical practice, dosing for hypertension in pregnancy (e.g., preeclampsia) often uses immediate-release nifedipine, not extended-release. For Adalat CC, the same dosing as in non-pregnant adults (30-90 mg once daily) is typically used, but titration should be cautious to avoid maternal hypotension. No formal dose adjustment is recommended, but careful monitoring and individualized titration are advised.
Isradipine is a dihydropyridine calcium channel blocker with high vascular selectivity; it causes less negative inotropic effect than nifedipine. It is used for hypertension and has been studied for Parkinson's disease but not FDA-approved for that indication. Its short half-life (8 hours) necessitates twice-daily dosing. Monitor for peripheral edema, headache, and dizziness. Avoid grapefruit juice as it increases drug levels. Use with caution in patients with aortic stenosis or heart failure with reduced ejection fraction.
Adalat CC (nifedipine extended-release) is a dihydropyridine calcium channel blocker used primarily for hypertension. Avoid in patients with unstable angina or within 4 weeks of myocardial infarction due to reflex tachycardia risk. May cause peripheral edema, especially in higher doses; consider adding an ACE inhibitor if edema is problematic. CYP3A4 inhibitors (e.g., grapefruit juice, macrolides, azole antifungals) significantly increase nifedipine levels; avoid coadministration. Tablet shell may appear intact in stool; this is normal.
Take this medication exactly as prescribed, usually twice daily.,Do not drink grapefruit juice while taking isradipine.,Avoid sudden discontinuation; consult your doctor before stopping.,Common side effects include swelling of ankles/feet, headache, and dizziness; report severe or persistent symptoms.,This medicine does not cure hypertension but helps control it; continue taking even if you feel well.
Swallow the tablet whole; do not crush or chew.,Do not consume grapefruit or grapefruit juice while taking this medication.,May cause dizziness or lightheadedness; avoid driving if affected.,Notify your doctor if you experience rapid heartbeat, swelling in the ankles or feet, or prolonged erections.,Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.
"The combination of isradipine, a dihydropyridine calcium channel blocker, with propranolol, a non-selective beta-blocker, can result in additive negative chronotropic and inotropic effects, leading to excessive bradycardia, hypotension, and potentially heart failure. Additionally, propranolol may mask the reflex tachycardia typically induced by isradipine's vasodilation, blunting compensatory mechanisms and increasing the risk of severe hypotension. Careful monitoring and dose adjustments are necessary when coadministering these agents."
"Isradipine, a calcium channel blocker, inhibits CYP3A4-mediated metabolism of saquinavir, a protease inhibitor used in HIV therapy. This leads to significantly increased saquinavir plasma concentrations, raising the risk of dose-related toxicities such as hepatotoxicity, QT prolongation, and gastrointestinal disturbances. Conversely, saquinavir may also inhibit isradipine metabolism, potentially causing enhanced hypotensive effects and peripheral edema."
"Amphotericin B, a polyene antifungal, can cause hypokalemia and hypomagnesemia due to renal tubular damage. Isradipine, a calcium channel blocker, may also affect electrolyte balance. Concomitant use increases the risk of severe hypokalemia, potentially leading to cardiac arrhythmias, QT prolongation, and neuromuscular effects. Close monitoring of serum electrolytes and ECG is essential."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISRADIPINE vs ADALAT CC, answered by our medical review team.
ISRADIPINE is a Calcium Channel Blocker that works by Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.. ADALAT CC is a Calcium Channel Blocker that works by Nifedipine, a dihydropyridine calcium channel blocker, inhibits calcium ion influx across cardiac and smooth muscle cell membranes, leading to vasodilation and decreased myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISRADIPINE and ADALAT CC depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISRADIPINE is: 2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.. The standard adult dose of ADALAT CC is: 30 mg orally once daily; may titrate to 60 mg or 90 mg once daily based on response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISRADIPINE and ADALAT CC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISRADIPINE is classified as Category C. Isradipine is a pregnancy category C drug. In animal studies, it caused embryotoxicity, fetotoxicity, and teratogenicity (skeletal anomalies) at doses 2-3 times the maximum recomme. ADALAT CC is classified as Category C. Adalat CC (nifedipine) is an extended-release formulation of nifedipine, a dihydropyridine calcium channel blocker. In animal studies, nifedipine has been associated with embryotox. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.